Crystal structure of MAGEA4 MHD-RAD18 R6BD reveals a flipped binding mode compared to AlphaFold2 prediction.

The article discusses the crystal structure of the MAGEA4 MHD-RAD18 R6BD complex and compares it to the AlphaFold2 prediction. The authors found that the binding mode of the RAD18 R6BD peptide in the crystal structure is flipped compared to the AlphaFold2 model. They also highlight the limitations of AlphaFold2, emphasizing that it is a statistical method based on existing experimental structures and may be biased by those structures. The authors conclude that their structural elucidation provides molecular evidence to clarify the confusion caused by the AlphaFold2 modeling and can aid in the development of MAGEA4-RAD18 antagonists for cancer treatment. [Extracted from the article]